Meeting
2021 ASCO Annual Meeting
Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
Authors
Michael Roost Clausen
Vejle Hospital, Vejle, Denmark
Michael Roost Clausen , Pieternella Lugtenburg , Martin Hutchings , Peter W. M. Johnson , Kim M. Linton , David John Lewis , Martine Chamuleau , Anna Sureda Balari , David Cunningham , Brian Elliott , Dena DeMarco , Kuo-mei Chen , Rogier Mous
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03625037
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7518)
DOI
10.1200/JCO.2021.39.15_suppl.7518
Abstract #
7518
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma.
First Author: Ki Hyun Kim
Poster
2023 ASCO Annual Meeting
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
First Author: Yasmin Karimi
Poster
2020 ASCO Virtual Scientific Program
Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.
First Author: Alison R. Sehgal